2026-10-16
-
Kongdy
Five Ways to Build Shelf-Life Evidence for a Pain Relief Patch OEM Programme: A 2026 Comparison Matr
A comparison matrix of the five defensible ways to build shelf-life evidence for a pain relief patch OEM programme: real-time long-term studies, accelerated stu......
Read More
2026-10-15
-
Kongdy
Reading the FY2025 FDA Warning Letter Data: What 303 Letters Mean for Pain Relief Patch Sellers in 2
FDA issued 303 warning letters to drug and biologic firms in FY2025 against 190 in FY2024, a 59 percent rise, and shortened its letter cycle by roughly one thir......
Read More
2026-10-15
-
Kongdy
Why FDA Warning Letter 721916 Matters for Pain Relief Patch Buyers: The Stability Evidence Problem T
FDA MARCS-CMS 721916 (Medical Products Laboratories, Inc., 2026-04-09) did not name a patch, but the deficiency at its centre does: without adequate stability s......
Read More